Literature DB >> 2667603

Response to vigabatrin in relation to seizure type.

R Michelucci1, C A Tassinari.   

Abstract

1. The purpose of this study was to evaluate the efficacy of vigabatrin in relation to the seizure type. 2. A review of the literature concerning the efficacy of vigabatrin in clinical trials was performed. 3. To date, vigabatrin has been used in a small number of patients with generalized seizures: in this group no significant effect was noted. 4. Vigabatrin was also given to a large number of patients with complex partial seizures: in this group vigabatrin produced a greater than 50% decrease in seizure frequency in almost 50% of patients included. 5. This review provides evidence that vigabatrin is effective in the treatment of complex partial seizures: patients with only one seizure type, low seizure frequency and unifocal EEG abnormalities are particularly expected to respond. 6. This implies that patients with complex partial seizures do not constitute an homogeneous group and that various parameters should be considered in the evaluation of the response to treatment.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2667603      PMCID: PMC1379690          DOI: 10.1111/j.1365-2125.1989.tb03472.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  14 in total

1.  Prognosis and therapy of complex partial seizures with barbiturates, hydantoins, and other drugs.

Authors:  C A Tassinari; J Roger
Journal:  Adv Neurol       Date:  1975

2.  Prognosis in childhood epilepsy. Follow-up study of 148 cases in which therapy had been suspended after prolonged anticonvulsant control.

Authors:  J Holowach; D L Thurston; J O'Leary
Journal:  N Engl J Med       Date:  1972-01-27       Impact factor: 91.245

3.  Long-term study of gamma-vinyl GABA in the treatment of epilepsy.

Authors:  S A Pedersen; P Klosterskov; L Gram; M Dam
Journal:  Acta Neurol Scand       Date:  1985-09       Impact factor: 3.209

4.  Gamma-vinyl-GABA: a single-blind trial in patients with epilepsy.

Authors:  L Gram; B B Lyon; M Dam
Journal:  Acta Neurol Scand       Date:  1983-07       Impact factor: 3.209

5.  Biochemical and clinical effects of gamma-vinyl GABA in patients with epilepsy.

Authors:  P J Schechter; N F Hanke; J Grove; N Huebert; A Sjoerdsma
Journal:  Neurology       Date:  1984-02       Impact factor: 9.910

6.  Double-blind study of vigabatrin in the treatment of drug-resistant epilepsy.

Authors:  C A Tassinari; R Michelucci; G Ambrosetto; F Salvi
Journal:  Arch Neurol       Date:  1987-09

7.  Long-term outcome in children with temporal lobe seizures. I: Social outcome and childhood factors.

Authors:  J Lindsay; C Ounsted; P Richards
Journal:  Dev Med Child Neurol       Date:  1979-06       Impact factor: 5.449

8.  gamma-Vinyl GABA: a double-blind placebo-controlled trial in partial epilepsy.

Authors:  L Gram; P Klosterskov; M Dam
Journal:  Ann Neurol       Date:  1985-03       Impact factor: 10.422

9.  [The partial epilepsies in childhood--evolution and prognosis factors (author's transl)].

Authors:  J Roger; C Dravet; P Menendez; M Bureau
Journal:  Rev Electroencephalogr Neurophysiol Clin       Date:  1981-12

10.  Classification of partial epilepsies according to the symptomatology of seizures: practical value and prognostic implications.

Authors:  P Pazzaglia; R D'Alessandro; A Lozito; E Lugaresi
Journal:  Epilepsia       Date:  1982-06       Impact factor: 5.864

View more
  8 in total

Review 1.  Drug treatment of epilepsy in the 1990s. Achievements and new developments.

Authors:  A Sabers; L Gram
Journal:  Drugs       Date:  1996-10       Impact factor: 9.546

Review 2.  The new generation of GABA enhancers. Potential in the treatment of epilepsy.

Authors:  S J Czuczwar; P N Patsalos
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

Review 3.  Vigabatrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control.

Authors:  S M Grant; R C Heel
Journal:  Drugs       Date:  1991-06       Impact factor: 9.546

Review 4.  A risk-benefit assessment of vigabatrin in the treatment of neurological disorders.

Authors:  J Srinivasan; A Richens
Journal:  Drug Saf       Date:  1994-05       Impact factor: 5.606

5.  Effects of vigabatrin on partial seizures and cognitive function.

Authors:  R A Grünewald; P J Thompson; R Corcoran; Z Corden; G D Jackson; J S Duncan
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-09       Impact factor: 10.154

Review 6.  Newer antiepileptic drugs. Towards an improved risk-benefit ratio.

Authors:  P N Patsalos; J W Sander
Journal:  Drug Saf       Date:  1994-07       Impact factor: 5.606

Review 7.  Place of newer antiepileptic drugs in the treatment of epilepsy.

Authors:  R Kälviäinen; T Keränen; P J Riekkinen
Journal:  Drugs       Date:  1993-12       Impact factor: 9.546

8.  Treatment of refractory complex partial seizures: role of vigabatrin.

Authors:  Elizabeth J Waterhouse; Kimberly N Mims; Soundarya N Gowda
Journal:  Neuropsychiatr Dis Treat       Date:  2009-10-12       Impact factor: 2.570

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.